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BAckground: The rates of cardiovascular (CV) events are highest in the period 
immediately after an initial MI but may remain elevated for an extended period 
of time. oBjectives: Evaluate long-term rates of CV events (recurrent myocar-
dial infarction (MI) and hospitalized stroke) and all cause mortality in patients 
with stable CAD after MI and in patients resembling those of the PEGASUS trial 
(NCT 01225562). Methods: Patients ≥ 50 years old (yo) with an MI followed by ≥ 
12 MI-free months (stable CAD) and no prior stroke were identified from a large 
claims database between 01/2007 and 11/2011. Inclusion and exclusion criteria were 
identified during a 12 month pre-MI baseline. Patients included in the PEGASUS-
like cohort were those having at least one additional risk factor (≥ 1 additional 
prior MI, Age≥ 65, diabetes or chronic non-end-stage renal disease (NESRD)). Rates 
of a composite endpoint (MI or stroke hospitalization or all-cause mortality) in the 
stable CAD and PEGASUS-like populations were estimated during follow-up (up 
to four years) after the stable CAD index. Due to data and population limitations, 
rates were compared in patients < 65 yo only. results: In the < 65 yo PEGASUS-like 
cohort, 24.4% had ≥ 1 additional prior MI, 76.1% had diabetes, and 27.4% had NESRD. 
Event rates for the PEGASUS-like (n= 5,357) and other stable CAD cohorts (n= 8,135) 
were 60/1,000 and 27/1,000 person-years (py), respectively (p< 0.0001). Hospitalized 
MI was the largest contributor to the composite endpoint (38/1,000 and 19/1,000 
py, respectively, p< 0.0001). Composite event rates in PEGASUS-like patients who 
were still MI-free 2 and 3 years after the index MI were 51/1,000 py and 44/1000 
py, respectively. conclusions: Stable CAD patients in the US meeting PEGASUS 
clinical trial criteria continue to have an elevated risk of major CV events and all 
cause mortality after several MI-free years.
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oBjectives: Several studies establish that the use of antidepressants associated 
with an increased risk of myocardial infarction (MI). However, available evidence 
on tricyclic antidepressants (TCAs) is conflicting. We therefore examined the 
association between TCAs use and risk of MI by conducting a detailed systematic 
review and meta-analysis using all observational studies published regarding this 
subject. Methods: A PubMed/MEDLINE search was conducted for studies pub-
lished up to 31stDecember, 2013. The studies were first evaluated for publication 
bias and heterogeneity. Pooled relative risk (RR) estimates and 95% confidence 
intervals (CIs) were calculated using random-effects model if heterogeneity pre-
sents or otherwise fixed-effects model. Cumulative meta-analysis, subgroup and 
sensitivity analyses were also performed. results: Six (3 cohort and 3 case-
control) studies satisfying the inclusion criteria were considered for this study. 
There was heterogeneity among the studies (pheterogeneity < 0.001, I2 = 98%) but no 
publication bias (Begg’s p = 0.70 and Egger’s p = 0.45). We observed no association 
between TCAs use and risk of MI (RR 1.14, 95% CI 0.67-1.96, p = 0.622). But, the 
sensitivity analysis revealed that the TCAs users are having 36% increased risk of 
MI after excluding one outlier (RR 1.36, 95% CI 1.10-1.67, p < 0.001) with less hetero-
geneity (pheterogeneity = 0.001, I2 = 78%). Subgroup analysis by study design shows 
that case-control studies are having positive association (RR 1.41, 95% CI 1.37-1.45, 
p < 0.001) but, cohort studies having no association (RR 0.94, 95% CI 0.40-2.23, 
p= 0.893) because of an outlier cohort study. Further, cumulative meta-analysis 
showed a change in trend of reporting MI risk from positive to no association in 
TCAs users between 1996 and 2011. conclusions: We found evidence that the 
use of TCAs was associated with elevated risk of MI. Further research is needed 
to identify the underlying biological mechanisms.
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oBjectives: To examine anticoagulant use and bleeding risk in patients with 
venous thromboembolism (VTE) in the U.S. clinical practice setting. Methods: 
Adult patients with VTE were selected from the MarketScan Commercial and 
Medicare Supplemental Databases between 07/01/2006 and 12/31/2011. Patients 
were required to have at least two outpatient visits with VTE diagnosis within 3 
weeks of each other or one inpatient VTE diagnosis. Patients were also required 
to have at least 6 months continuous enrollment in the 6 months prior to first 
VTE diagnosis. Cases consisted of VTE patients who experienced a major bleeding 
event after VTE diagnosis. Control patients were those who did not experience any 
bleed after VTE diagnosis and were 1:1 matched with cases by propensity score. 
Anticoagulant use was categorized as current use (within 2 weeks prior to bleeding), 
past use (more than 2 weeks prior to bleeding), and never used prior to bleeding or 
during follow-up period. Multivariate logistic regression was performed to examine 
the association between anticoagulant use and major bleeding. results: A total of 
4166 bleeding cases and matched controls were included in the analysis. Compared 
to controls, cases were more likely to currently use anticoagulants (25.6% vs. 16.7%, p 
< .0001). Multivariate logistic regression showed that use of warfarin (past: OR= 1.25; 
current: OR= 1.48), parenteral anticoagulant (past: OR= 1.91; current: OR= 4.59), and 
parenteral anticoagulant plus warfarin (past: OR= 1.36; current: OR= 1.87) were sig-
nificantly associated with increased risk for major bleeding (p< 0.001), after adjusting 
for demographic and clinical factors. Results were similar with sensitivity analysis 
using 1:1 hard matched data on age, sex, type of VTE, and index VTE diagnosis 
date. conclusions: In patients with VTE, current and past use of anticoagulants 
was associated with increased risk of major bleeding. Study results suggest more 
effective anticoagulants demonstrating lower bleeding risk are needed to treat and 
prevent recurrence of VTE.
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oBjectives: Dronedarone is a non-iodinated benzofuran derivative approved by 
FDA in July 2009. It is used for the treatment of abnormal heart rhythm in patients 
with a history of atrial fibrillation or atrial flutter. The recent evidence suggests there 
is a potential risk of serious cardiovascular adverse events associated with the use 
of dronedarone, especially among patients with permanent atrial fibrillation. The 
objective is to assess the association between use of dronedarone and the risk of 
serious cardiovascular adverse events and other health outcomes. Methods: A 
literature search of peer-reviewed publications relevant to the study was performed 
using PubMed® from 1996 to 2013. Eight clinical trials with a total of 10,800 patients 
enrolled were identified for this study. A meta-analysis of randomized controlled 
trials comparing patients with or without dronedarone was conducted. The drone-
darone group included patients who took dronedarone, and patients who took 
placebo (7 studies) or amiodarone (1 study) were considered as the control group. 
Outcomes included all-cause mortality, cardiovascular mortality and heart failure 
exacerbation. Review Manager 5.2 was used for data analysis. results: Compared 
to the control group, the use of dronedarone did not significantly increase the risks 
of all-cause mortality (Risk Ratio [RR], 1.27; 95% Confidence interval [CI], 0.80 to 
2.02), cardiovascular mortality (RR, 1.31; 95% CI, 0.53 to 3.24) and heart failure exac-
erbations (RR, 1.19; 95% CI, 0.88 to 1.62). However, after conducting the sensitivity 
analysis which excluded the ATHENA study (the FDA approval of dronedarone was 
based on this trial), we found dronedarone was statistically significant in increasing 
the risk of all-cause mortality (RR, 1.70; CI, 1.13 to 2.56), cardiovascular mortality (RR, 
2.13; 95% CI, 1.10 to 4.15) and heart failure exacerbations (RR, 1.42; 95% CI, 1.07 to 
1.89). conclusions: The health care professionals should prescribe dronedarone 
cautiously for patients with cardiovascular risk factors.
CArdiOVAsCUlAr disOrders – Cost studies
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oBjectives: To develop a model for estimating reductions in the number of events 
and costs of myocardial infarction (MI) and ischemic stroke (IS) for a US health 
plan as a result of implementing routine testing with multi-tiered cardiovascular 
risk markers of vascular inflammation including hsCRP, Lp-PLA2 and myeloper-
oxidase. Methods: An Excel model was developed to estimate reductions in MI 
and IS as well as reductions in the per-member-per-month (PMPM) and five-year 
costs before testing costs due to biomarker-based testing for a hypothetical US 
health plan. Inputs for the model included: incidence rates of MI and IS, direct costs 
associated with MI and IS, lab results of multi-marker testing, graded risk ratios of 
MI and IS based on combinations of abnormal risk markers, patient monitoring 
and intervention costs, and preventative pharmacotherapy. Preventative pharma-
cotherapy use and costs were based on an analysis of pharmacy claims data. Costs 
savings (2012 USD) were assessed for patients undergoing multi-marker testing 
as compared to patients with lipid panel testing only. Clinical expertise was relied 
upon for inputs relating to treatment response and changes in preventative phar-
macotherapy. Direct costs, incidence rates, and risk ratios were obtained from litera-
ture. results: For a health plan with 1,000,000 members, an estimated 21,104 MI 
and 22,589 IS events would occur over five years. Implementing this multi-tiered risk 
assessment of inflammatory biomarkers for patients ≥ 35 years old would reduce 
MI and IS events by 2,018 and 1,848, respectively, yielding almost $180.6m in cost 
savings ($3.01 PMPM). Results were sensitive to changes in treatment response. 
Nonetheless, cost savings were observed for most scenarios. conclusions: This 
study suggests that health plans can realize substantial cost savings by prevent-
ing MI and IS events after implementing routine biomarker testing. Cost savings 
before testing costs could reach more than $3.01 PMPM for a typical US health plan.
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oBjectives: Percutaneous Coronary Intervention (PCI) is used to treat Acute 
Coronary Syndrome (ACS). Currently ACCF/AHA/SCAI PCI guidelines recommend 
use of antithrombin agents (bivalirudin or heparin) in combination with antiplatelet 
agents (oral P2Y12 inhibitors and/or GPIIb/IIIa inhibitors). Bivalirudin has demon-
strated reduced bleeding events vs. heparin+GPI; though, GPI use has declined over 
the past 10 years. Cangrelor, a novel, rapid on/off-set IV P2Y12, reduced ischemic 
events vs. clopidogrel in the CHAMPION program. The aim of our analysis was to 
quantify the impact of using cangrelor and bivalirudin together in PCI from a US 
hospital perspective. Methods: A decision analytic model based on current clinical 
practice was developed to estimate the annual impact of using heparin+/-GPI+/-
clopidogrel (base case) vs. bivalirudin+cangrelor+bailout GPI (scenario). We used 
data from RCTs to estimate event rates (mortality, myocardial infraction, stent 
thrombosis, ischemia-driven revascularization, and major/minor bleeding). Patient 
and GPI mix was derived from an analysis of Premier’s Perspectives Database. GPI 
use in cangrelor patients was based on the CHAMPION Phoenix study. Event costs 
were obtained from published literature and inflation-adjusted to 2013 dollars. 
Drug costs were based on 2013 wholesale acquisition costs. To estimate the clinical 
value of using bivalirudin+cangrelor, we set their costs to $0. results: For a hypo-
